Free tool · 2 minutes
Do I qualify?
Answer a few quick questions to see if you may qualify for our physician-supervised medical weight loss program, including GLP-1 medications like semaglutide and tirzepatide. Your answers stay in your browser unless you choose to have your results emailed to you.
Medically reviewed by Dr. Roger Eduardo, MD, FASMBS, Board-Certified General Surgeon. Last reviewed August 2026.
Book a consultation →Your result
This is general educational information, not a medical diagnosis, not a prescription, and not a confirmation that any medication is right for you. Eligibility and safety are determined by Dr. Eduardo after a full evaluation, and your results are reviewed during that consultation. Screening thresholds reflect FDA labeling for Wegovy and Zepbound.
Next step, made easy
Want Dr. Eduardo's team to reach out?
Leave your details and we'll follow up within one business day to help you book. We only send your contact details, not your quiz answers.
Based on where you landed
Plan your path
What could you lose?
Enter your numbers and compare projected weight loss across every path. Each medication shows a band: the clinical-trial average at the top, down to what people realistically see when they stay on treatment. Surgery figures are durable, real-world outcomes. Nothing you enter is stored or sent anywhere.
Projected weight over time
Percent-of-body-weight curves from published outcomes, applied to your weight. Shaded band is the trial average (top) down to real-world with continued use (bottom).
The band shows what you can expect if you stay on treatment. Most people don't. About 2 in 3 stop GLP-1 within the first year, and stopping brings much of the weight back. That is why the medicine is a long-term commitment, and why a durable procedure is worth weighing.
Medication curves: trial average from STEP 1 (semaglutide, NEJM 2021) and SURMOUNT-1 (tirzepatide, NEJM 2022); real-world continued-use figures from Samuels et al. (Diabetes Obesity & Metabolism 2025) and Gasoyan (Obesity 2025); about 64.8% discontinue within 12 months (Rodriguez, JAMA Network Open 2025). Retatrutide (TRIUMPH) is investigational and not yet FDA-approved. Surgery curves reflect total body-weight loss consistent with SM-BOSS (Peterli, JAMA 2018), STAMPEDE, and the SADI-S systematic review (Spinos, Obes Surg 2021); the monthly trajectory is smoothed for illustration. These are population averages. Your results depend on adherence, dose, biology, and starting point. Educational only, not medical advice.
Projected results at 52 weeks
Ranked by projected total loss for your inputs. Medication rows show the real-world figure with continued use, with the trial best case beside it.
FAQ
About this quiz
Can't find your answer here? Call us at (470) 742-1832 or book a consultation, we'll answer every question before you commit to anything.
No. This quiz is an educational screening tool that reflects general eligibility framing, typically a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition, per FDA labeling for Wegovy and Zepbound. It does not store or transmit your answers and is not medical advice. Only a physician can confirm whether a GLP-1 or other weight-loss medication is right for you, after a full evaluation.
No. The quiz runs entirely in your browser. Nothing you enter is stored or sent anywhere unless you choose to book a consultation afterward. No personal health information is collected.
Our physician-supervised program uses FDA-approved medications including semaglutide and tirzepatide, as well as oral options such as phentermine where clinically appropriate. Dr. Eduardo individualizes every plan after a medical evaluation.
Start your journey
Ready for a real answer?
A quiz is a start, a consultation is the answer. Book with Dr. Eduardo to confirm whether a GLP-1 or other weight-loss program is right for you.
